Combination of bleomycin, etoposide and cisplatin (BEP) versus etoposide and cisplatin (EP) in patients with good risk nonseminomatous germ cell tumors (NSGCT)

被引：0
|
作者：
Tryakin, A. [1 ]
Fedyanin, M. [1 ]
Bulanov, A. [1 ]
Titov, D. [1 ]
Mitin, A. [2 ]
Sergeev, J. [3 ]
Figurin, K. [2 ]
Fainstein, I. [3 ]
Matveev, V. [2 ]
Zakharova, T. [4 ]
Kostjakova, L. [5 ]
Garin, A. [1 ]
Tjulandin, S. [1 ]
机构：
[1] NN Blokhin Russian Canc Res Ctr, Clin Pharmacol & Chemotherapy, Moscow, Russia
[2] NN Blokhin Russian Canc Res Ctr, Urol, Moscow, Russia
[3] NN Blokhin Russian Canc Res Ctr, Radiosurg, Moscow, Russia
[4] NN Blokhin Russian Canc Res Ctr, Pathomorphol, Moscow, Russia
[5] NN Blokhin Russian Canc Res Ctr, Radiol, Moscow, Russia
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31428-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2610
引用
收藏
页码：S515 / S515
页数：1
相关论文
共 50 条
  • [41] TREATMENT OF POOR RISK NONSEMINOMATOUS GERM-CELL TUMOR (NSGCT) PATIENTS (PTS) WITH CARBOPLATIN(CBDCA)+ETOPOSIDE(E) + BLEOMYCIN (B)
    MOTZER, RJ
    BOSL, GJ
    YAGODA, A
    GOLBEY, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 202 - 202
  • [42] Neurologic late toxicity in testicular cancer patients treated with bleomycin, etoposide and cisplatin (bep) combination chemotherapy.
    Bavbek, SE
    Basaran, M
    Saip, S
    Eralp, Y
    Sakar, B
    Onat, H
    ANNALS OF ONCOLOGY, 2000, 11 : 78 - 78
  • [43] Prognostic factors and survival in germ cell cancer (GCC) patients treated with bleomycin, etoposide, and cisplatin (BEP): A population-based study
    Kier, M. G. G.
    Lauritsen, J.
    Mortensen, M. S.
    Bandak, M.
    Andersen, K. K.
    Hansen, M. K.
    Agerbaek, M.
    Holm, N. V.
    Dalton, S. O.
    Johansen, C.
    Daugaard, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
    Feldman, Darren R.
    Hu, James S.
    Patil, Sujata
    Reuter, Victor E.
    Srinivas, Sandy
    Stadler, Walter Michael
    Costello, Brian Addis
    Milowsky, Matthew I.
    Appleman, Leonard Joseph
    Dorff, Tanya B.
    Bromberg, Maria
    Joseph, Gabriella
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] TREATMENT OF POOR-RISK GERM-CELL TUMORS WITH HIGH-DOSE CISPLATIN AND ETOPOSIDE COMBINED WITH BLEOMYCIN
    DAUGAARD, G
    RORTH, M
    ANNALS OF ONCOLOGY, 1992, 3 (04) : 277 - 282
  • [46] Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
    Feldman, Darren R.
    Hu, James
    Srinivas, Sandy
    Stadler, Walter Michael
    Costello, Brian Addis
    Appleman, Leonard Joseph
    Milowsky, Matthew I.
    Patil, Sujata
    Bromberg, Maria
    Nolan, Patrick
    Dorff, Tanya B.
    Reuter, Victor E.
    Al-Ahmadie, Hikmat
    Funt, Samuel
    Bajorin, Dean F.
    Bosl, George J.
    Quinn, David I.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group
    Bamias, Aristotelis
    Aravantinos, Gerassimos
    Kastriotis, Ioannis
    Alivizatos, Gerassimos
    Anastasiou, Ioannis
    Christodoulou, Christos
    Gyftaki, Reveka
    Kalofonos, Haralambos P.
    Dimopoulos, Meletios A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (02) : 189 - 193
  • [48] THE OPTIMIZATION OF CARBOPLATIN DOSE IN CARBOPLATIN, ETOPOSIDE AND BLEOMYCIN COMBINATION CHEMOTHERAPY FOR GOOD PROGNOSIS METASTATIC NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS
    CHILDS, WJ
    NICHOLLS, EJ
    HORWICH, A
    ANNALS OF ONCOLOGY, 1992, 3 (04) : 291 - 296
  • [49] A randomized trial of 72-hour infusional bleomycin in BEP (cisplatin, etoposide, and bleomycin) versus conventional weekly bleomycin in patients with metastatic IGCCCG good prognosis disease
    Vinnicombe, Sarah
    Harland, Stephen John
    Joffe, Johnathan K.
    Huddart, Robert
    Mazhar, Danish
    Birtle, Alison J.
    White, Jeff D.
    Wilson, Peter
    Marshall, Marita
    Sarker, Shah-Jalal
    Shamash, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin
    Xiao, H
    Mazumdar, M
    Bajorin, DF
    Sarosdy, M
    Vlamis, V
    Spicer, J
    Ferrara, J
    Bosl, GJ
    Motzer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2553 - 2558
12345